An Overview of the ACC/AHA Recommendations on Cholesterol Management in People With Diabetes

Abstract

Get full access to this article

View all access options for this article.

References

American Diabetes Association. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes. Diabetes Care. 2019;42(Suppl. 1):S103-S123.

Benjamin

Muntner

Alonso

, et al. Heart disease and stroke statistics 2019 update. Circulation. 2019;139: e56-e528.

Bhatt

Gabriel

Miller

, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl JMed. 2019;380:11-22.

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent

Blackwell

Emberson

, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.

Grundy

Stone

Bailey

, et al. 2018 AHA/ACC/ AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046-e1081.

Kazemian

Shebi

McCann

, et al. Evaluation of the cascade of diabetes care in the United States, 2005-2016. JAMA Intern Med. 2019;179(10):1376-1385.

National Lipid Association position statement on the use of icosapent ethyl in high and very-high risk patients. https://www.lipid.org/nla/nla-position-use-icosapent-ethyl-high-and-very-high-risk-patients. Accessed October 20, 2019.